Abstract OT1-03-02: MP0274-CP101: A Phase 1, First-in-human, Single-Arm, Multi-Center, Open-Label, Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of MP0274 in Patients with Advanced HER2-positive Solid Tumors
semanticscholar(2018)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要